Bildkälla: Stockfoto

Xbrane Biopharma: FDA Resubmission in 2022 - Redeye

Redeye leaves a short comment on today’s press release from Xbrane stating that the company intends to file a resubmission of its BLA for Xlucane during 2022.

Redeye leaves a short comment on today’s press release from Xbrane stating that the company intends to file a resubmission of its BLA for Xlucane during 2022.
Börsvärldens nyhetsbrev
ANNONSER